CO4480041A1 - FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNOSUPPRESSIVE ACTIVITY - Google Patents
FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNOSUPPRESSIVE ACTIVITYInfo
- Publication number
- CO4480041A1 CO4480041A1 CO95057748A CO95057748A CO4480041A1 CO 4480041 A1 CO4480041 A1 CO 4480041A1 CO 95057748 A CO95057748 A CO 95057748A CO 95057748 A CO95057748 A CO 95057748A CO 4480041 A1 CO4480041 A1 CO 4480041A1
- Authority
- CO
- Colombia
- Prior art keywords
- monoclonal antibody
- fab fragment
- hla
- fragments
- presenting cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REIVINDICACION NUMERO UN FRAGMENTO FAB QUE CONSTA DE UN FRAGMENTO FAB DE INMUNOGLOBULINA SEIS REGIONES DETERMINANTES COM- PLEMENTARIAMENTE, QUE ESTAN CONTENIDOS DENTRO DE DICHO SEGMENTO FAB, EN EL CUAL DE UNA A SEIS DE DICHAS REGIONES ETEMIANTES COMPLEMENTARIAMENTE SON REGIONES DETERMINANTES COMPLEMENTARIAMENTE DE UN ANTICUERPO MONOCLONAL QUE TIENE LAS SIGUIENTES PROPIEDADES: 1) EL ANTICUERPO MONOCLONAL SE UNE AL PRIMER DOMI- NIO DEL HLA-DR, 2) EL ANTICUERPO MONOCLONAL ES CITOTOXICO PARA LAS CELULAS PRESENTADORAS DEL ANTIGENO, QUE EXPRESAN EL HLA-DR, 3) EL ANTICUERPO MONOCLONAL REDUCE LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN LAS CELULAS PRESEN- TADORAS DEL ANTIGENO.- REIVINDICACION NUMERO UNA COMPOSICION FARMACEUTICA FLUIDA QUE CONSTA DE: 1) UN SOPORTE FLUIDO FARMACEUTICAMENTE ACEPTABLE; Y 2) UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN FRAGMENTO FAB COMO SE HA REIVINDICADO EN CUALQUIE- RA DE LAS REIVINDICACIONES 2 A REIVINDICACION NUMERO UN PROCEDIMIENTO PARA LA PREPARACION DE UN FRAG- MENTO FAB COMO SE DEFINE EN UNA CUALQUIERA DE LAS REIVINDICACIONES 1 A 4, CARACTERIZADO PORQUE UN ANTICUERPO MONOCLONAL COMO SE HA DEFINIDO EN LAS REIVINDICACIONES 1 o 2, SE ESCINDE MEDIANTE PEPSINA Y LOS FRAGMENTOS FAB SE AISLAN MEDIANTE METODOS YA CONOCIDOS EN EL ESTADO ACTUAL DE LA ESPECIALIDAD.CLAIM NUMBER A FAB FRAGMENT CONSISTING OF A FAB FRAGMENT OF IMMUNOGLOBULIN SIX DETERMINING REGIONS COMPLEMENTARELY, WHICH ARE CONTAINED WITHIN SUCH A FULLY-SIGNIFY REGULAR COMPONENT REGULAR SEVERING REGULATORS IT HAS THE FOLLOWING PROPERTIES: 1) THE MONOCLONAL ANTIBODY JOINS THE FIRST DOMAIN OF HLA-DR, 2) THE MONOCLONAL ANTIBODY IS CYTOTOXIC FOR ANTIGEN PRESENTING CELLS, WHICH EXPRESS HLA-DR, 3) THE MONOCLONAL ANTIBODY SENSITIVITY OF THE EXPRESSION OF THE HLA-DR IN THE PRESENTING CELLS OF THE ANTIGEN.- CLAIM NUMBER A FLUID PHARMACEUTICAL COMPOSITION THAT CONSISTS OF: 1) A PHARMACEUTICALLY ACCEPTABLE FLUID SUPPORT; AND 2) A THERAPEUTICALLY EFFECTIVE AMOUNT OF A FAB FRAGMENT AS CLAIMED IN ANY OF CLAIMS 2 A CLAIM IS A PROCEDURE FOR THE PREPARATION OF A FAB FRAGMENT, AS DEFINED IN ANY 4 OF CLAIMS 1. CHARACTERIZED BECAUSE A MONOCLONAL ANTIBODY AS DEFINED IN CLAIMS 1 or 2, IS HIDDEN THROUGH PEPSINE AND FAB FRAGMENTS ARE ISOLATED THROUGH METHODS ALREADY KNOWN IN THE CURRENT STATUS OF SPECIALTY.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35091594A | 1994-12-07 | 1994-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4480041A1 true CO4480041A1 (en) | 1997-07-09 |
Family
ID=23378740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO95057748A CO4480041A1 (en) | 1994-12-07 | 1995-12-05 | FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNOSUPPRESSIVE ACTIVITY |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0787151A1 (en) |
| JP (1) | JP2001506122A (en) |
| CN (1) | CN1168679A (en) |
| AR (1) | AR002005A1 (en) |
| AU (1) | AU4256096A (en) |
| BR (1) | BR9509902A (en) |
| CA (1) | CA2206471A1 (en) |
| CO (1) | CO4480041A1 (en) |
| CZ (1) | CZ172497A3 (en) |
| FI (1) | FI972430A (en) |
| HU (1) | HUT77342A (en) |
| IL (1) | IL116228A0 (en) |
| MA (1) | MA23739A1 (en) |
| NO (1) | NO972522L (en) |
| PE (1) | PE52996A1 (en) |
| PL (1) | PL320610A1 (en) |
| TR (1) | TR199501542A2 (en) |
| WO (1) | WO1996017874A1 (en) |
| ZA (1) | ZA9510195B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| AU5588099A (en) | 1998-08-28 | 2000-03-21 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
| ATE365749T1 (en) * | 2000-05-12 | 2007-07-15 | Gpc Biotech Ag | HUMAN PEPTIDES/PROTEINS THAT CAUSE OR EFFECT THE KILLING OF CELLS, INCLUDING LYMPHOID TUMOR CELLS |
| US7521047B2 (en) | 2000-05-12 | 2009-04-21 | Gpc Biotech Ag | Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| EP1156062A1 (en) * | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| AU2002340168A1 (en) | 2001-10-11 | 2003-06-17 | Protein Design Labs Inc. | Treatment of prostate cancer by inhibitors of ncam2 |
| US7262278B2 (en) | 2001-10-15 | 2007-08-28 | Kirin Beer Kabushiki Kaisha | Anti-HLA-DR antibody |
| CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| US20110243841A1 (en) * | 2010-04-01 | 2011-10-06 | Immunomedics, Inc. | Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells |
| KR102647825B1 (en) * | 2021-07-22 | 2024-03-14 | 서울대학교산학협력단 | Anti-HLA-DP monoclonal antibody and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3269354D1 (en) * | 1981-06-25 | 1986-04-03 | Univ Leland Stanford Junior | Allele specific immunotherapeutic method and dosage form |
| DE69028713T3 (en) * | 1989-12-27 | 2004-05-13 | Centocor, Inc. | CHIMERAL IMMUNOGLOBULINE FOR CD4 RECEPTORS |
| DE69233628T2 (en) * | 1991-07-25 | 2007-04-26 | Biogen Idec Inc., San Diego | Recombinant antibodies for human therapy |
-
1995
- 1995-11-25 CA CA002206471A patent/CA2206471A1/en not_active Abandoned
- 1995-11-25 EP EP95941017A patent/EP0787151A1/en not_active Withdrawn
- 1995-11-25 JP JP51728896A patent/JP2001506122A/en active Pending
- 1995-11-25 PL PL95320610A patent/PL320610A1/en unknown
- 1995-11-25 CZ CZ971724A patent/CZ172497A3/en unknown
- 1995-11-25 WO PCT/EP1995/004648 patent/WO1996017874A1/en not_active Application Discontinuation
- 1995-11-25 CN CN95196662A patent/CN1168679A/en active Pending
- 1995-11-25 AU AU42560/96A patent/AU4256096A/en not_active Abandoned
- 1995-11-25 HU HU9702311A patent/HUT77342A/en unknown
- 1995-11-25 BR BR9509902A patent/BR9509902A/en not_active Application Discontinuation
- 1995-11-30 ZA ZA9510195A patent/ZA9510195B/en unknown
- 1995-12-01 IL IL11622895A patent/IL116228A0/en unknown
- 1995-12-04 PE PE1995286338A patent/PE52996A1/en not_active Application Discontinuation
- 1995-12-05 AR ARP950100448A patent/AR002005A1/en unknown
- 1995-12-05 CO CO95057748A patent/CO4480041A1/en unknown
- 1995-12-07 TR TR95/01542A patent/TR199501542A2/en unknown
- 1995-12-07 MA MA24090A patent/MA23739A1/en unknown
-
1997
- 1997-06-03 NO NO972522A patent/NO972522L/en unknown
- 1997-06-06 FI FI972430A patent/FI972430A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT77342A (en) | 1998-03-30 |
| CZ172497A3 (en) | 1997-10-15 |
| NO972522L (en) | 1997-08-06 |
| CA2206471A1 (en) | 1996-06-13 |
| CN1168679A (en) | 1997-12-24 |
| FI972430A0 (en) | 1997-06-06 |
| NO972522D0 (en) | 1997-06-03 |
| EP0787151A1 (en) | 1997-08-06 |
| PE52996A1 (en) | 1996-12-12 |
| AU4256096A (en) | 1996-06-26 |
| WO1996017874A1 (en) | 1996-06-13 |
| MX9704225A (en) | 1997-09-30 |
| IL116228A0 (en) | 1996-03-31 |
| BR9509902A (en) | 1997-10-21 |
| MA23739A1 (en) | 1996-07-01 |
| ZA9510195B (en) | 1996-06-07 |
| PL320610A1 (en) | 1997-10-13 |
| AR002005A1 (en) | 1998-01-07 |
| JP2001506122A (en) | 2001-05-15 |
| FI972430A (en) | 1997-06-06 |
| TR199501542A2 (en) | 1996-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mazor et al. | Immunogenicity of therapeutic recombinant immunotoxins | |
| Nicolson et al. | Low-dose Btk inhibitors selectively block platelet activation by CLEC-2 | |
| Qin et al. | CD4 monoclonal antibody pairs for immunosuppression and tolerance induction | |
| Csernok et al. | Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. | |
| Rose | Role of anti-vimentin antibodies in allograft rejection | |
| US4676980A (en) | Target specific cross-linked heteroantibodies | |
| Okada et al. | A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement | |
| Rabie et al. | Diverging signaling events control the pathway of GPVI down-regulation in vivo | |
| Panzer et al. | IgM exacerbates glomerular disease progression in complement-induced glomerulopathy | |
| CO4480041A1 (en) | FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNOSUPPRESSIVE ACTIVITY | |
| CY1111193T1 (en) | HUMAN CDR-MISCELLANEOUS ANTIBODIES AND THEIR ANTIBODY SHRIMP | |
| CO4850562A1 (en) | PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES | |
| ATE204480T1 (en) | MONOCLONAL ANTIBODY WHICH BINDS SPECIFICALLY TO VASCULARIZED TUMOR DOTHELIUM AND USES THEREOF | |
| ATE470714T1 (en) | ANTIBODIES TO DOUBLE INTEGRINS, COMPOSITIONS, METHODS AND USES | |
| Hansen et al. | A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules | |
| Bordron et al. | Anti‐endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies | |
| Sun et al. | Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis | |
| Terness et al. | The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope. | |
| Ravindranath et al. | HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies | |
| Ongaro et al. | A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo | |
| DK0845998T3 (en) | Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated | |
| Jensenius et al. | Total immunoglobulin of rat thymocytes and thoracic duct lymphocytes | |
| Zeiser | Biology-driven developments in the therapy of acute graft-versus-host disease | |
| Levitz et al. | Binding of Cryptococcus neoformans to heterologously expressed human complement receptors | |
| ATE248189T1 (en) | ANTIBODIES AGAINST VASP (VASODILATOR-STIMULATED PHOSPHOPROTEIN), HYBRIDOMA CELLS FOR THEIR OBTAINING, AND THEIR USE |